Savara Secures Up to $200M Non-Dilutive Financing from Hercules Capital
Savara Secures Up to $200 Million in Non-Dilutive Debt Financing from Hercules Capital Savara Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare respiratory diseases, has announced…
FDA Approves CABOMETYX® for Advanced Neuroendocrine Tumors
FDA Approves CABOMETYX® (Cabozantinib) for Advanced Neuroendocrine Tumors, Expanding Treatment Options Exelixis, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment…
Viz.ai Identifies Hypertrophic Cardiomyopathy Earlier in Workflow
Viz.ai AI-Powered Solution Identifies Hypertrophic Cardiomyopathy Earlier, Enhancing Clinical Care Viz.ai, a leading company in AI-powered disease detection and intelligent care coordination, has announced compelling new clinical data demonstrating the…
Coya Therapeutics Advances Treg-Derived Exosome Program
Coya Therapeutics Advances Treg-Derived Exosome Program Coya Therapeutics, Inc. (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function, has provided…
Global Pharma Leader Adopts ValGenesis iClean for Digital Cleaning Validation
Global Pharma Leader Adopts ValGenesis iClean for Digital Cleaning Validation ValGenesis, Inc., a global leader in digital validation lifecycle management solutions, has announced a significant milestone in its collaboration with…
Epicrispr Biotech Raises $68M for FSHD Epigenetic Therapy Trial
Epicrispr Biotech Raises $68M for FSHD Epigenetic Therapy Trial Epicrispr Biotechnologies, a pioneering biotechnology company dedicated to developing curative therapies, has announced the successful first close of its Series B…
RenovoRx TAMP™ Pre-Clinical Results to Be Awarded at SIR 2025
RenovoRx TAMP™ Pre-Clinical Results to Be Awarded at SIR 2025 RenovoRx, Inc. (“RenovoRx” or the “Company”), a pioneering life sciences company dedicated to advancing targeted oncology therapies, is pleased to…
Merck Licenses HRS-5346 for Cardiovascular Disease from Hengrui
Merck Licenses HRS-5346 for Cardiovascular Disease from Hengrui Merck, known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a leading global…
Xcellbio Partners with Planet Innovation to Advance Cell Therapy Manufacturing
Xcell Biosciences Partners with Planet Innovation and Royal Perth Hospital to Advance Cell Therapy Manufacturing Xcell Biosciences Australia Pty Ltd (Xcellbio), a subsidiary of the San Francisco-based biotechnology company specializing…
FDA Approves Blujepa (Gepotidacin) for uUTIs in Adults & Teens
FDA Approves Blujepa (Gepotidacin) for uUTIs in Adults & Teens GSK plc has announced that the US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of…
Veracyte’s WGS-Based MRD Test Shows Accuracy in Bladder Cancer
Veracyte’s Whole-Genome Sequencing-Based MRD Test Shows High Accuracy for Muscle-Invasive Bladder Cancer Detection Veracyte, Inc., a leader in cancer diagnostics, has announced groundbreaking new data demonstrating the accuracy and effectiveness…
$13.5B Oligonucleotide Synthesis Market Outlook to 2035: Pharma & Biopharma Dominate
$13.5B Oligonucleotide Synthesis Market Outlook to 2035: Pharma & Biopharma Dominate The global oligonucleotide synthesis market is poised for significant growth, expanding from USD 4.8 billion in the current year…